Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes

Endocrine Journal

Volumn 54, Issue 4, 2007, Pages 613-618

  Maegawa, Hiroshi ^a   Nishio, Yoshihiko ^a   Nakao, Keiko ^a   Ugi, Satoshi ^a   Maeda, Kendo ^a   Uzu, Takashi ^a   Kashiwagi, Atsunori ^a  

^a SHIGA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

Author keywords

Forearm blood flow; Pioglitazone; Reactive hyperemia; Strain gauge plethysmography

Indexed keywords

ADIPONECTIN; GLUCOSE; INSULIN; PIOGLITAZONE;

ADULT; AGED; ARTICLE; BLOOD FLOWMETRY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN SENSITIVITY; LOW DRUG DOSE; MALE; METABOLIC PARAMETERS; NON INSULIN DEPENDENT DIABETES MELLITUS; SHORT COURSE THERAPY; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM;

ADIPONECTIN; AGED; BLOOD GLUCOSE; BODY MASS INDEX; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPEREMIA; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PLETHYSMOGRAPHY; REGIONAL BLOOD FLOW; THIAZOLIDINEDIONES;

EID: 34548672388     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K06-203     Document Type: Article

References (34)

1. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR Jr, Lerman A (2000) Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation 101: 948-954.
2. Schachinger V, Britten MB, Zeiher AM (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101: 1899-1906.
3. Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari AM, Paolisso G, Marfella R, Giugliano D (2002) Post-prandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 39: 1145-1157.
4. Chan NN, Vallance P, Colhoun HM (2003) Endothelium-dependent and -independent vascular dysfunction in type 1 diabetes: role of conventional risk factors, sex, and glycemic control. Arterioscler Thromb Vasc Biol 23: 1048-1054.
5. McVeigh GE, Brennan GM, Johnstone GD, McDermott BJ, McGrath LT, Henry WR, Andrews JW, Hayes JR (1992) Impaired endothelium-dependent and independent vasodilation in patients with type II (non-insulin-dependent) diabetes mellitus. Diabetologia 35: 771-776.
6. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD (1996) Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest 97: 2601-2610.
7. Mullen MJ, Kharbanda RK, Cross J, Donald AE, Taylor M, Vallance P, Deanfield JE, MacAllister RJ (2001) Heterogeneous nature of flow-mediated dilatation in human conduit arteries in vivo: relevance to endothelial dysfunction in hypercholesterolemia. Circ Res 88: 145-151.
8. Vita JA (2005) Endothelial function and clinical outcome. Heart 91: 1278-1279.
9. Horio T, Suzuki M, Takamisawa I, Suzuki K, Hiuge A, Yoshimasa Y, Kawano Y (2005) Pioglitazone-induced insulin sensitization improves vascular endothelial function in nondiabetic patients with essential hypertension. Am J Hypertens 18: 1626-1630.
10. Campia U, Matuskey LA, Panza JA (2006) Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors. Circulation 113: 867-875.
11. Sourij H, Zweiker R, Wascher TC (2006) Effects of pioglitazone on endothelial function, insulin sensitivity, and glucose control in subjects with coronary artery disease and new-onset type 2 diabetes. Diabetes Care 29: 1039-1045.
12. Linder L, Kiowski W, Bühler FR, Lüscher TF (1990) Indirect evidence for release of endothelium-derived relaxing factor in human forearm circulation in vivo: blunted response in essential hypertension. Circulation 81: 1762-1767.
13. Panza JA, Quyyumi AA, Brush JE Jr, Epstein SE (1990) Abnormal endothelium-dependent vascular relaxation in patients with essential hypertension. N Engl J Med 323: 22-27.
14. Takeshita A, Imaizumi T, Ashihara T, Yamamoto K, Hoka S, Nakamura M (1982) Limited maximal vasodilator capacity of forearm resistance vessels in normotensive young men with a familial predisposition to hypertension. Circ Res 50: 671-677.
15. Higashi Y, Sasaki S, Nakagawa K, Matsuura H, Kajiyama G, Oshima T (2001) A noninvasive measurement of reactive hyperemia that can be used to assess resistance artery endothelial function in humans. Am J Cardiol 87: 121-125.
16. Tagawa T, Imaizumi T, Endo T, Shiramoto M, Harasawa Y, Takeshita A (1994) Role of nitric oxide in reactive hyperemia in human forearm vessels. Circulation 90: 2285-2290.
17. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y (1999) Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Comm 257: 79-83.
18. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC (1985) Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412-419.
19. Kawano H, Motoyama T, Hirashima O, Hirai N, Miyao Y, Sakamoto T, Kugiyama K, Ogawa H, Yasue H (1999) Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery. J Am Coll Cardiol 34: 146-154.
20. Ceriello A, Taboga C, Tonutti L, Quagliaro L, Piconi L, Bais B, Da Ros R, Motz E (2002) Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 106: 1211-1218.
21. Shimabukuro M, Higa N, Chinen I, Yamakawa K, Takasu N (2006) Effects of a single administration of acarbose on postprandial glucose excursion and endothelial dysfunction in type 2 diabetic patients: a randomized crossover study. J Clin Endocrinol Metab 91: 837-842.
22. Verma S, Anderson TJ (2002) Fundamentals of endothelial function for the clinical cardiologist. Circulation 105: 546-549.
23. Verma S, Buchanan MR, Anderson TJ (2003) Endothelial function testing as a biomarker of vascular disease. Circulation 108: 2054-2059.
24. Steinberg HO, Tarshoby M, Monestel R, Hook G, Cronin J, Johnson A, Bayazeed B, Baron AD (1997) Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation. J Clin Invest 100: 1230-1239.
25. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, Lloyd JK, Deanfield JE (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340: 1111-1115.
26. Hijmering ML, Stroes ES, Pasterkamp G, Sierevogel M, Banga JD, Rabelink TJ (2001) Variability of flow mediated dilation: consequences for clinical application. Atherosclerosis 157: 369-373.
27. Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N, Tagawa T, Ueda S, Shimomura I, Funahashi T, Matsuzawa Y (2003) Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab 88: 3236-3240.
28. Sakuta H, Suzuki T, Yasuda H, Ito T (2005) Adiponectin levels and cardiovascular risk factors in Japanese men with type 2 diabetes. Endocr J 52: 241-244.
29. Shimizu H, Oh IS, Tsuchiya T, Ohtani KI, Okada S, Mori M (2006) Pioglitazone increases circulating adiponectin levels and subsequently reduces TNF-alpha levels in Type 2 diabetic patients: a randomized study. Diabet Med 23: 253-257.
30. Koshiyama H, Shimono D, Kuwamura N, Minamikawa J, Nakamura Y (2001) inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86: 3452-3456.
31. Satoh N, Ogawa Y, Usui T, Tagami T, Kono S, Uesugi H, Sugiyama H, Sugawara A, Yamada K, Shimatsu A, Kuzuya H, Nakao K (2003) Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26: 2493-2499.
32. Martens FM, Visseren FL, de Koning EJ, Rabelink TJ (2005) Short-term pioglitazone treatment improves vascular function irrespective of metabolic changes in patients with type 2 diabetes. J Cardiovasc Pharmacol 46: 773-778.
33. Raitakari OT, Lai N, Griffiths K, McCredie R, Sullivan D, Celermajer DS (2000) Enhanced peripheral vasodilation in humans after a fatty meal. J Am Coll Cardio 36: 417-422.
34. Flemmer M, Scott J (2001) Mechanism of action of thiazolidinediones. Curr Opin Investig Drugs 2: 1564-1567.